Ascentage pharma announces pricing of top-up placement

Rockville, md. and suzhou, china, july 14, 2025 (globe newswire) -- ascentage pharma group international inc. (nasdaq: aapg; hkex: 6855) (“ascentage” or the “company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced the pricing of 22 million ordinary shares, par value $0.0001 per share, of the company (the “placement shares”), at a price of hkd68.60 per share, in the offering by dajun yang dynasty trust, an affiliate of the company's chief executive officer, dajun yang, m.d., ph.d. (the “vendor”) in an offshore transaction outside the united states to non-u.s. persons in reliance on regulation s under the securities act of 1933, as amended (the “securities act”)(the “offshore placement”), for aggregate gross proceeds of approximately hkd1,509.2 million (or approximately us$192.3 million based on exchange rate of 1 usd to 7.85 hkd), before deducting placing fees and other offering expenses. the offshore placement, which was oversubscribed by eight times, is expected to close on july 17, 2025.
AAPG Ratings Summary
AAPG Quant Ranking